Detection of color vision defects in chloroquine retinopathy

Ophthalmology

Volumn 106, Issue 9, 1999, Pages 1799-1804

  Linda Vu, B L ^a,c   Easterbrook, Michael ^a   Hovis, Jeffery K ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF WATERLOO   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLOR VISION DEFECT; COLOR VISION TEST; CONTROLLED STUDY; DRUG EFFECT; EYE TOXICITY; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; RETINOPATHY; VISUAL FIELD;

EID: 1842826758     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0161-6420(99)90338-x     Document Type: Article

References (28)

1. Hobbs HE, Sorsby A, Freedman A. Retinopathy following chloroquine therapy. Lancet 1959;2:478-80.
2. Easterbrook M. Long-term course of antimalarial maculopathy after cessation of treatment. Can J Ophthalmol 1992;27: 237-9.
3. Easterbrook M. Is corneal deposition of antimalarial any indication of retinal toxicity? Can J Ophthalmol 1990;25:249-51.
4. Easterbrook M. The use of Amsler grids in early chloroquine retinopathy. Ophthalmology 1984;91:1368-72.
5. Rynes RI, Bernstein HN. Ophthalmologic safety profile of antimalarial drugs. Lupus 1993;2(Suppl):S17-9.
6. Leid J, Plantey J, Leid V. A protocol for monitoring treatment with synthetic anti-malarial drugs. In: Cavonius CR, ed. Colour vision deficiencies XIII: proceedings of the Thirteenth Symposium of the Int'l Research Group on Colour Vision Deficiencies, 1995. Dordrecht; Boston: Kluwer Academic Publishers, 1997; 231-8 (Documenta ophthalmologica Proceedings series; v. 59) [editorial].
7. Easterbrook M. Current concepts in monitoring patients on antimalarials. Aust N Z J Ophthalmol 1998;26:101-3.
8. Okun E, Gouras P, Bernstein H, von Sallmann L. Chloroquine retinopathy: a report of eight cases with ERG and dark-adaptation findings. Arch Ophthalmol 1963;69:59-71.
9. Nozik RA, Weinstock FJ, Vignos PJ Jr. Ocular complications of chloroquine. A series and case presentation with a simple method for early detection of retinopathy. Am J Ophthalmol 1964;58:774-8.
10. Carr RE, Gouras P, Gunkel RD. Chloroquine retinopathy. Early detection by retinal threshold test. Arch Ophthalmol 1966;75:171-8.
11. Henkind P, Carr RE, Siegel IM. Early chloroquine retinopathy: clinical and functional findings. Arch Ophthalmol 1964; 71:157-65.
12. Nylander U. Ocular damage in chloroquine therapy. Acta Ophthalmol (Copenh) 1966;44:335-48.
13. Percival SPB, Meanock I. Chloroquine: ophthalmological safety, and clinical assessment in rheumatoid arthritis. Br Med J 1968;3:579-84.
14. Bartel PR, Roux P, Robinson E, et al. Visual function and long-term chloroquine treatment. S Afr Med J 1994;84:32-4.
15. Easterbrook M. Ocular effects and safety of antimalarial agents. Am J Med 1988;85(4A):23-9.
16. Jaeger W, Krastel H. Colour vision deficiencies caused by pharmacotherapy. In: Verriest G, ed. Color Vision Deficiencies VIII: Proc. Int'l Research Group on Colour Vision Deficiencies, 1985. Dordrecht: Martinus Nijhoff/Dr. W. Junk Publishers, 1987;37-52 (Doc Ophthalmol Proc Ser; 46).
17. Grützner P. Acquired color vision defects secondary to retinal drug toxicity. Ophthalmologica 1969;158:Suppl:592-604.
18. Adams AJ, Rodic R. Use of desaturated and saturated versions of the D-15 test in glaucoma and glaucoma-suspect patients. In: Verriest G, ed. Color Vision Deficiencies VI: Proc. Int'l Research Group on Colour Vision Deficiencies, 1981. The Hague: Dr W. Junk Publishers, 1982;419-24 (Doc Ophthalmol Proc Ser; 33).
19. Hovis JK, Cawker CL, Cranton D. Normative data for the standard Pseudoisochromatic Plates Part 2. J Am Optom Assoc 1990;61:913-20.
20. Inherited and acquired colour vision deficiencies: fundamental aspects and clinical studies, Foster DH, ed. Boca Raton: CRC Press, 1991 (Vision and visual dysfunction; v. 7).
21. Ruddock KH. Light transmission through the ocular media and macular pigment and its significance for psychophysical investigation. In: Jameson D, Hurvich LM, eds. Visual psychophysics. Berlin; New York: Springer-Verlag, 1972;455 (Handbook of sensory physiology; v. 714).
22. Blair JR, Mieler WF. Retinal toxicity associated with commonly encountered systemic agents. Int Ophthalmol Clin 1995;35:137-56.
23. Contestabile MT, Suppressa F, Tonelli G, et al. Evaluation of hydroxychloroquine retinal toxicity. Annals of Ophthalmology 1996;28:376-83.
24. Easterbrook M. Dose relationships in patients with early chloroquine retinopathy. J Rheumatol 1987;14:472-5.
25. Mackenzie AH. Pharmacologic actions of 4-aminoquinoline compounds. Am J Med 1983;75(1A):5-10.
26. Weiner A, Sandberg MA, Gaudio AR, et al. Hydroxychloroquine retinopathy. Am J Ophthalmol 1991;112:528-34.
27. Finbloom DS, Silver K, Newsome DA, Gunkel R. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol 1985;12:692-4.
28. Johnson MW, Vine AK. Hydroxychloroquine therapy in massive total doses without retinal toxicity. Am J Ophthalmol 1987;104:139-44.